| Session 1. Recent Advances in Therapeutic Antibody R&D |
|
As a major part of recombinant protein therapeutics, antibody therapeutics have made a remarkable progress of industry while the whole pharmaceutical market has been in stagnant growth rate. First session will provide latest updates in global R&D in antibody therapeutics regarding engineering antibodies for improved efficacy, and the therapeutic significance of human antibodies. Monoclonal antibodies and novel targets discovery will be discussed and the development of monoclonal antibody for the treatment of B-cell Malignancy will be presented as an example. The last topic in the first session is R&D of therapeutic antibodies which include past experience, current trend and future direction of this field. |
| Chair : Se-Ho KIM, Research Director, Readearch Center, Green Cross Corp. |
 |
| - Therapeutic Antibodies and Their Target Discovery |
| Youngwoo PARK, Principal Research Scientist, Korea Research Institute of Bioscience & Biotech. |
|
   |
|
- Development of Monoclonal Antibody for the Treatment of B-Cell
Malignancies |
| Sang Hoon LEE, Senior ScientistII, Molecular & Cellular Pharmacology, Exelixis |
|
|
|
- Generation of Therapeutic Antibodies
: Past Experience, Current Trend and Future Direction |
| Naoya TSURUSHITA, Cofounder, JN Biosciences LLC. |
|
|
|
|
| Session 2. Process Development of Therapeutic Antibodies |
|
Although Therapeutic antibody field has shown rapid growth, limitation of validated target raised the interest in efficacy enhancement through the antibody engineering. This second session will discuss in depth about current status of local and global antibody manufacturing capacities, problem and checkpoint in the process development for eventual antibody development. The first time will be addressed assessment of cell engineering strategies for improved therapeutic antibody production in CHO cells. What will follow is ADCC and CDC enhancement technology for next generation therapeutic antibodies. The final topic is the role of the analytical tools in the development of therapeutic antibodies. |
| Chair : Hosung MIN, Head, Samsung Electronics |
|
- Assessment of Cell Engineering Strategies for Improved Therapeutic
Antibody Production in CHO Cells |
| Gyun Min LEE, Professor, Dept. of Biological Sciences, Korea Advanced Institute of Science and Tech. |
|
|
|
- ADCC and CDC Enhancement Technology for Next-Generation
Therapeutic Antibodies |
| Kenya SHITARA, Director, Antibody Business Office, Kyowa Hakko Kogyo Co., Ltd. |
|
|
|
| - The Analytical Role in the Development of Therapeutic Antibodies |
| Zheru ZHANG, Director, R&D, Celltrion, Inc. |
|
  |
|
|
| Session 3. Forecasts by Industries in Therapeutic Antibody Development |
|
Due to advantage of the cost-effective and shorter development time, many Korean pharmaceutical companies are trying to develop the therapeutic antibody. This session will discuss on the global forecast of antibody therapeutics market in the short and long term from the viewpoint of therapeutics industries in Korea. The developmental programs of therapeutic antibodies will be presented by Hanwha Chemical Corp., Korea Greencross Corp., and Samsung Advanced Institute of Technology. |
Chair : Young Woo PARK, Senior Researcher, Korea Research Institute of Bioscience and Biotechnology |
|
| - Strategy of New Mab Therapy in Hanwha group |
| Soon Jae PARK, Senior Vice President, Bio, Hanwha Group |
|
 |
|
- HBV Neutralizing Human Monoclonal Antibody: From Bench to Clinic
: HBV Neutralizing Human Antibody |
| Se-Ho KIM, Research Director, Research Center, Green Cross Corp. |
|
|
|
| - Beyond Antibodies : Possibilities and Limitations |
| Hosung MIN, Head, Antibody Engineering, Bio & Health Group, Samsung Electronics |
|
|
|
|
|
